The Effect of Rosiglitazone on Adipocyte-derived Cytokines in Nondiabetics With the Metabolic Syndrome.
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2012
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Metabolic syndrome
- Focus Pharmacodynamics
- 01 Mar 2010 Status changed from active, no longer recruiting to completed.
- 01 Mar 2010 Results published in Pharmacotherapy.
- 01 Mar 2010 Primary endpoint 'Adiponectin levels' has been met according to results published in Pharmacotherapy.